We want to reveal new perspectives in cancer therapy.

Empowering Patients – Accelerating Science

Each year numerous new and promising substances in cancer medicine reach application maturity. Getting these drugs to official approval is a long, expensive process during which new therapies are not accessible to many patients. iuvando was founded to make innovative therapies available to all during the clinical trial phase and to shorten the time to official approval.

iuvando Principles

Our research work is conducted on the following guidelines to which we feel ethically bound:

We are an independent and neutral third party.

Our studies research functions independently of sponsors or drug makers – which means: All currently published therapy trials are listed in our data base. We remain neutral.

We research without judging.

On the initiative of a patient or physician, iuvando prepares an overview of clinical trials according to formal criteria. We are not rating the results of the study research and make no statements regarding the chances of success of individual therapies studied. The medical rating of search results is left exclusively to the treating physician.

We respect the existing doctor-patient relationship.

Iuvando does not pretend to be a medical authority to the patient and makes no statements regarding an individual illness or treatment plan. The relationship of trust between the patient and his/her treating physician remains untouched.

Who we are – get to know iuvando!

Dr. Mridul Agrawal and Dr. Benjamin Hanfstein can look back on many years of experience as physicians and scientists in cancer and leukemia research. They are united in their enthusiasm for targeted therapy approaches which have already brought immense improvements in certain areas of cancer treatment for patients. The development of these medicines prior to their official approval is a very expensive process that can take years, during which new therapies are not accessible to many patients. iuvando was founded to make innovative therapies available early in their clinical trial phase, and to shorten the time to official approval.

Menu